Table 2.

Effects of ANG II and PE on transfer functions related to myogenic and TGF autoregulatory mechanisms

	Myogenic					TGF
	Frequency, Hz	Fractional Gain	Phase Peak, degrees	Coherence at 0.05-0.1 Hz	Slope of Gain Reduction, db/decade	Frequency, Hz	Fractional Gain
Baseline	0.23 ± 0.01	2.4 ± 0.2	78 ± 7	0.7 ± 0.03	42 ± 10	0.05 ± 0.001	0.7 ± 0.1
ANG II	0.27 ± 0.01	3.0 ± 0.2*	106 ± 6*	0.5 ± 0.03*	62 ± 6	0.04 ± 0.003	0.6 ± 0.1
Baseline	0.24 ± 0.01	2.3 ± 0.2	75 ± 7	0.7 ± 0.05	40 ± 3	0.04 ± 0.002	0.6 ± 0.1
PE	0.25 ± 0.01	1.6 ± 0.1*†	59 ± 3†	0.7 ± 0.06†	24 ± 12†	0.04 ± 0.003	0.8 ± 0.1†
ANOVA effects
Baseline vs. Drug	P < 0.005	NS	NS	P < 0.05	NS	NS	NS
ANG II vs. PE	NS	P < 0.005	P < 0.005	NS	P < 0.05	NS	NS
Interaction	P = 0.07	P < 0.001	P < 0.005	P < 0.05	P < 0.05	NS	P < 0.05

Values are expressed as means ± SE. ANG II (n = 11; 125 ng·kg⁻¹·min⁻¹), PE (n = 8; 50 mg·kg⁻¹·day⁻¹). TGF, tubuloglomerular feedback; NS, not significant.

^*P < 0.05 vs. baseline.

^†P < 0.05 vs. ANG II.